SequelSEC

Revolution Medicines, Inc. RVMD

Biological Products, (No Diagnostic Substances) · CIK 0001628171 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Revolution Medicines, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Revolution Medicines, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
RevenueUnavailable$0$0$0$0$742.00K$0Unavailable$7.01M$15.33M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailable-$216.31M-$175.71M-$156.64M-$140.86M-$179.98M-$123.25MUnavailable-$75.16M-$61.71M
Net incomeUnavailable-$194.57M-$156.29M-$133.23M-$116.00M-$161.54M-$108.43MUnavailable-$68.10M-$56.51M
Research & developmentUnavailable$188.10M$151.75M$134.93M$118.02M$148.48M$107.74MUnavailable$68.95M$66.13M
Weighted-average diluted sharesUnavailableUnavailableshares 166.84Mshares 165.14Mshares 164.73MUnavailableshares 109.23MUnavailableshares 94.83MUnavailable
Pretax incomeUnavailable-$195.32M-$156.29M-$133.23M-$116.00M-$161.19M-$112.30MUnavailable-$68.10M-$56.63M
Income tax expenseUnavailable-$753.00K$0$0$0$343.00K-$3.87MUnavailable$0-$123.00K
Diluted EPSUnavailableUnavailable$-0.94$-0.81$-0.70Unavailable$-0.99Unavailable$-0.72Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailable$28.21M$23.96M$21.71M$22.84M$32.24M$15.51MUnavailable$13.22M$10.91M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Revolution Medicines, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Cash & equivalents$383.74M$543.06M$201.26M$275.71M$288.43M$696.15M$358.40MUnavailable$427.22M$161.41M
Total assets$2.35B$2.56B$1.76B$1.81B$1.91B$2.06B$984.23MUnavailable$1.07B$811.93M
Current assets$2.08B$2.33B$1.58B$1.62B$1.73B$1.88B$824.47MUnavailable$922.75M$660.18M
Total liabilities$723.21M$293.10M$196.70M$189.59M$182.90M$235.51M$146.77MUnavailable$121.03M$126.74M
Current liabilities$290.42M$163.91M$110.86M$105.33M$93.72M$143.85M$85.54MUnavailable$54.64M$61.98M
Total equity incl. NCI$1.63B$2.27B$1.57B$1.62B$1.73B$1.83B$837.46MUnavailable$952.22M$685.19M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$14.61M$14.61M$14.61M$14.61M$14.61M$14.61M$14.61MUnavailable$14.61M$14.61M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$64.62M$54.43M$24.46M$29.32M$32.38M$61.79M$29.63MUnavailable$19.91M$21.31M

Cash flow

Revolution Medicines, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Operating cash flowUnavailable-$138.29M-$130.42M-$128.17M-$160.56M-$120.56M-$100.50MUnavailable-$62.39M-$61.79M
Capital expendituresUnavailable$1.22M$3.52M$2.40M$3.17M$2.32M$2.54MUnavailable$1.76M$2.88M
Investing cash flowUnavailable-$392.90M-$21.47M$107.94M-$247.97M-$380.40M$77.35MUnavailable$4.00M-$7.10M
Financing cash flowUnavailable$873.80M$77.29M$7.50M$810.00K$839.35M$1.01MUnavailable$324.20M$51.36M
Net change in cashUnavailable$342.61M-$74.59M-$12.72M-$407.72M$338.39M-$22.13MUnavailable$265.81M-$17.53M
Stock-based compensationUnavailable$22.44M$20.78M$19.78M$16.21M$25.43M$13.67MUnavailable$9.70M$8.32M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$1.74M$1.64M$1.64M$1.54MUnavailableUnavailableUnavailable$1.20M$1.20M

Derived

Revolution Medicines, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Free cash flowUnavailable-$139.51M-$133.94M-$130.57M-$163.73M-$122.88M-$103.03MUnavailable-$64.15M-$64.66M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable-24256.5%UnavailableUnavailable-1071.5%-402.5%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable-16560.6%UnavailableUnavailable-914.6%-421.8%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable3426.8%UnavailableUnavailable138.3%54.2%
Current ratio7.14x14.20x14.24x15.42x18.45x13.06x9.64xUnavailable16.89x10.65x
Revenue YoY growthUnavailable-100.0%UnavailableUnavailable-100.0%-95.2%-100.0%Unavailable-7.4%62.1%
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable-21770.5%UnavailableUnavailableUnavailable-368.6%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable20010.9%UnavailableUnavailable983.0%431.4%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable312.3%UnavailableUnavailable25.1%18.8%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RVMD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2022-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.